// App-Quantinova.ai

2574 : A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.

Researchers

Presenter

  • Manish R. Patel

Principal Investigators

  • Marwan Fakih

  • Anthony J. Olszanski

  • Albert C. Lockhart

  • Alexander E. Drilon

  • Siqing Fu

  • Lyudmila Bazhenova

  • Rupal Patel

  • Jennifer W. Oliver

  • Pratik S. Multani

  • Ding Wang

Medical Centers

  • Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

  • Roswell Park Cancer Institute, Buffalo, NY

  • Fox Chase Cancer Center, Temple Health, Philadelphia, PA

  • Washington University School of Medicine, St. Louis, MO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, La Jolla, San Diego, CA

  • Ignyta, Inc, San Diego, CA

  • Henry Ford Health System, Detroit, MI

Locations

  • United States

Companies

  • Ignyta, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Circulating tumor cells

  • Ret Proto-Oncogene

Drug/Treatment

  • RXDX105

Outcome

  • Unknown

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT01877811

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved